<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151129">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01132729</url>
  </required_header>
  <id_info>
    <org_study_id>VALA-T1000-PVFS-1</org_study_id>
    <nct_id>NCT01132729</nct_id>
  </id_info>
  <brief_title>Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions</brief_title>
  <official_title>A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Valacyclovir Caplets Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roxane Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roxane Laboratories</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to prove the bioequivalence of Valacyclovir
      Hydrochlorothiazide Caplet under fasting conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>bioequivalence determined by statistical comparison Cmax</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Herpes Zoster</condition>
  <condition>Shingles</condition>
  <condition>Genital Herpes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valacyclovir Hydrochloride</intervention_name>
    <description>1000 mg caplet</description>
    <other_name>Valtrex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No clinically significant abnormal findings on the physical examination, medical
             history, or clinical laboratory results during screening

        Exclusion Criteria:

          -  Positive test for HIV, Hepatitis B, or Hepatitis C.

          -  Treatment with known enzyme altering drugs.

          -  History of allergic or adverse response to valacyclovir hydrochloride or any
             comparable or similar product.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Copa, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRACs Institute, Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRACs Institute, Ltd.</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <lastchanged_date>October 6, 2010</lastchanged_date>
  <firstreceived_date>May 25, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Elizabeth Ernst, Director, Drug Regulatory and Medical Affairs</name_title>
    <organization>Roxane Laboratories, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Herpes Genitalis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Valacyclovir</mesh_term>
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
